VONJO Drug Patent Profile
✉ Email this page to a colleague
When do Vonjo patents expire, and when can generic versions of Vonjo launch?
Vonjo is a drug marketed by Cti Biopharma Corp and is included in one NDA. There are three patents protecting this drug.
This drug has seventy-seven patent family members in twenty-seven countries.
The generic ingredient in VONJO is pacritinib citrate. One supplier is listed for this compound. Additional details are available on the pacritinib citrate profile page.
DrugPatentWatch® Generic Entry Outlook for Vonjo
Vonjo will be eligible for patent challenges on February 28, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 25, 2030. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for VONJO
International Patents: | 77 |
US Patents: | 3 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 2 |
Patent Applications: | 3 |
Drug Prices: | Drug price information for VONJO |
What excipients (inactive ingredients) are in VONJO? | VONJO excipients list |
DailyMed Link: | VONJO at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VONJO
Generic Entry Date for VONJO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for VONJO
US Patents and Regulatory Information for VONJO
VONJO is protected by six US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of VONJO is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting VONJO
Oxygen linked pyrimidine derivatives
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: USE OF PACRITINIB FOR INHIBITING JANUS ASSOCIATED KINASE 2(JAK2)
Oxygen linked pyrimidine derivatives
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF MYELOFIBROSIS WITH PACRITINIB
11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.- 1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF MYELOFIBROSIS WITH PACRITINIB
11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.- 1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: USE OF PACRITINIB FOR INHIBITING JANUS ASSOCIATED KINASE 2(JAK2)
Oxygen linked pyrimidine derivatives
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: USE OF PACRITINIB FOR INHIBITING JANUS ASSOCIATED KINASE 2(JAK2)
Oxygen linked pyrimidine derivatives
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF MYELOFIBROSIS WITH PACRITINIB
FDA Regulatory Exclusivity protecting VONJO
TREATMENT OF ADULTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY (POST-POLYCYTHEMIA VERA OR POST-ESSENTIAL THROMBOCYTHEMIA) MYELOFIBROSIS (MF) WITH A PLATELET COUNT BELOW 50 X 10^9/L
Exclusivity Expiration: ⤷ Try a Trial
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cti Biopharma Corp | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Cti Biopharma Corp | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Cti Biopharma Corp | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for VONJO
When does loss-of-exclusivity occur for VONJO?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 4724
Estimated Expiration: ⤷ Try a Trial
Patent: 4133
Estimated Expiration: ⤷ Try a Trial
Australia
Patent: 09325147
Patent: 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 0922736
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 46058
Estimated Expiration: ⤷ Try a Trial
China
Patent: 2282148
Estimated Expiration: ⤷ Try a Trial
Croatia
Patent: 0150428
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 76499
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 76499
Estimated Expiration: ⤷ Try a Trial
Hong Kong
Patent: 61877
Estimated Expiration: ⤷ Try a Trial
Israel
Patent: 9379
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 69748
Estimated Expiration: ⤷ Try a Trial
Patent: 12511571
Estimated Expiration: ⤷ Try a Trial
Malaysia
Patent: 0005
Patent: 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO(19.3.1.1(2,6).1(8,12))HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE SALT
Estimated Expiration: ⤷ Try a Trial
Mexico
Patent: 11006206
Estimated Expiration: ⤷ Try a Trial
New Zealand
Patent: 3223
Patent: 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1 (2,6).1(8, 12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE SALT
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 76499
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 76499
Estimated Expiration: ⤷ Try a Trial
Russian Federation
Patent: 27970
Estimated Expiration: ⤷ Try a Trial
Patent: 11126173
Estimated Expiration: ⤷ Try a Trial
Singapore
Patent: 1907
Patent: 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6)1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27)J16,21,23-DECAENE CITRATE SALT
Estimated Expiration: ⤷ Try a Trial
South Africa
Patent: 1104032
Patent: 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6)1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27)J16,21,23-DECAENE CITRATE SALT
Estimated Expiration: ⤷ Try a Trial
South Korea
Patent: 1729918
Estimated Expiration: ⤷ Try a Trial
Patent: 110106344
Patent: 11- (2-PYRROLIDIN-1-YL-ETHOXY) -14, 19-DIOXA-5, 7, 26-TRIAZA-TETRACYCLO [19. 3. 1. 1 (2, 6) 1 (8, 12)]HEPTACOSA-1 (25), 2 (26), 3, 5, 8, 10, 12 (27) J16, 21, 23-DECAENE CITRATE SALT
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 36558
Estimated Expiration: ⤷ Try a Trial
Taiwan
Patent: 49705
Estimated Expiration: ⤷ Try a Trial
Patent: 1028426
Patent: 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering VONJO around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Hong Kong | 1123282 | 氧連接的嘧啶衍生物 (OXYGEN LINKED PYRIMIDINE DERIVATIVES) | ⤷ Try a Trial |
South Korea | 101729918 | ⤷ Try a Trial | |
World Intellectual Property Organization (WIPO) | 2010068181 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |